Abivax Aktie
| 89,80EUR | -4,50EUR | -4,77% |
WKN DE: A14UQC / ISIN: FR0012333284
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 26 | 24 | 61 | 69 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 75 | 48 | 286 | 171 | 551 |
| Summe Anlagevermögen | 36 | 25 | 41 | 35 | 33 |
| Summe Aktiva | 110 | 73 | 327 | 205 | 584 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 82 | 71 | 131 | 165 | 129 |
| Summe Eigenkapital | 29 | 2 | 196 | 41 | 455 |
| Summe Passiva | 110 | 73 | 327 | 205 | 584 |
Adresse
| 7-11 Boulevard Haussmann, 75009 Paris | |
| Telefon | +33 (1) 53-83-09-63 |
| Internet | http://www.abivax.com |
Management
|
Camilla Soenderby
Independent Director |
|
Christopher Rabbat
Head-Medical Affairs & Vice President |
|
Corinna Zur Bonsen-Thomas
Independent Director |
|
David Zhang
Chief Strategy Officer |
|
Didier Blondel
Chief Financial Officer, Secretary & EVP |
|
Dominik Höchli
Director |
|
Fabio Cataldi
Chief Medical Officer |
|
Hema Keshava
Senior Vice President-Finance |
|
Ida Hatoum
Chief People & Compliance Officer |
|
June H. Lee
Director |
|
Keith Fournier
Senior Vice President-Global Regulatory Affairs |
|
Marc M. P. de Garidel
Chief Executive Officer & Director |
|
Maurus de la Rosa
Senior Vice President-Research |
|
Michael Nesrallah
Chief Commercial Officer |
|
Patrick Malloy
Senior Vice President-Investor Relations |
|
Pierre Courteille
Chief Business Officer |
|
Sylvie Louise Grégoire
Chairman |
|
Troy A. Ignelzi
Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.